Serum Protein Markers for Glioma

About this trial

“The first aim is to identify biomarkers that could distinguish between two different grades of brain cancer.

The second aim is to determine if changes in the levels of the identified biomarkers relate to disease progression and patient outcome.”

Patient Profile

All patients with suspected newly diagnosed brain cancer (glioma) who are planned to have surgical treatment.

Patients will be asked to donate blood samples at various time points before and during their treatment and once every 3-6 months post-treatment for up to 5 years, depending on the path of their disease.

These blood samples will be taken at time of normal blood work; therefore participants will experience no additional discomfort or pain and no additional visits will be required.

Where’s this trial being run?

Beaumont Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information


Here’s a list of questions you may have for your doctor or local cancer research team.

Summary Data

Name: Serum Protein Markers for Glioma
Number: 08-13
Full Title:

Are gliomas in adults associated with a unique identifying serum protein signature?

Principal Investigator: Dr Verena Murphy (Cancer Trials Ireland)
Type: In-House

Cancer Trials Ireland.

Recruitment Started: Global: Not Applicable
Ireland: July 2009
Global Recruitment Target: Not Applicable
Ireland Recruitment Target: 130